Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKRO Akero Therapeutics	$48.29 +0.7%	$51.59	$21.34 ▼ $58.40	$3.86B	-0.28	1.41 million shs	534,807 shs
CRMD CorMedix	$13.56 +0.3%	$12.33	$4.87 ▼ $17.43	$1.01B	1.71	1.93 million shs	2.94 million shs
LNTH Lantheus	$59.16 +5.4%	$72.29	$47.25 ▼ $118.21	$4.02B	0.14	1.20 million shs	2.83 million shs
PTGX Protagonist Therapeutics	$56.04 -0.3%	$54.13	$33.31 ▼ $60.60	$3.49B	2.33	930,379 shs	500,857 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKRO Akero Therapeutics	+0.74%	-0.75%	-6.68%	-2.08%	+79.32%
CRMD CorMedix	+3.52%	+11.92%	+23.58%	+10.28%	+169.32%
LNTH Lantheus	+1.80%	+4.37%	-21.55%	-24.90%	-42.97%
PTGX Protagonist Therapeutics	-0.04%	-0.86%	+1.83%	+22.48%	+35.49%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKRO Akero Therapeutics	3.9484 of 5 stars	3.5	2.0	4.7	3.3	0.8	0.0
CRMD CorMedix	2.2516 of 5 stars	3.4	1.0	0.0	2.0	0.0	1.9
LNTH Lantheus	4.7495 of 5 stars	4.4	1.0	4.2	3.3	2.5	1.9
PTGX Protagonist Therapeutics	1.9812 of 5 stars	2.5	3.0	0.0	3.1	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKRO Akero Therapeutics	3.00	Buy	$81.57	68.92% Upside
CRMD CorMedix	2.88	Moderate Buy	$16.71	23.26% Upside
LNTH Lantheus	2.71	Moderate Buy	$105.50	78.33% Upside
PTGX Protagonist Therapeutics	3.00	Buy	$67.20	19.91% Upside

Current Analyst Ratings Breakdown

Latest CRMD, AKRO, LNTH, and PTGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	LNTH Lantheus	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Hold	$111.00 ➝ $63.00
8/8/2025	CRMD CorMedix	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $17.00
8/7/2025	PTGX Protagonist Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/7/2025	LNTH Lantheus	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$112.00 ➝ $73.00
8/7/2025	LNTH Lantheus	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$120.00 ➝ $70.00
8/7/2025	PTGX Protagonist Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$67.00 ➝ $69.00
8/4/2025	AKRO Akero Therapeutics	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
8/4/2025	AKRO Akero Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$76.00
7/16/2025	LNTH Lantheus	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
6/30/2025	CRMD CorMedix	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/30/2025	CRMD CorMedix	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	$12.82 per share	N/A
CRMD CorMedix	$43.47M	23.29	N/A	N/A	$2.96 per share	4.58
LNTH Lantheus	$1.53B	2.62	$7.61 per share	7.77	$17.16 per share	3.45
PTGX Protagonist Therapeutics	$434.43M	8.02	$4.50 per share	12.45	$10.74 per share	5.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKRO Akero Therapeutics	-$252.06M	-$2.00	N/A	N/A	N/A	N/A	-15.84%	-14.59%	N/A
CRMD CorMedix	-$17.93M	$0.75	18.08	14.43	N/A	42.11%	42.73%	34.19%	10/29/2025 (Estimated)
LNTH Lantheus	$312.44M	$3.76	15.73	9.38	N/A	17.82%	34.06%	19.10%	11/5/2025 (Estimated)
PTGX Protagonist Therapeutics	$275.19M	$0.70	80.06	N/A	N/A	24.88%	8.12%	7.41%	11/6/2025 (Estimated)

Latest CRMD, AKRO, LNTH, and PTGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/8/2025	Q2 2025	AKRO Akero Therapeutics	-$0.97	-$0.86	+$0.11	-$0.86	N/A	N/A
8/7/2025	Q2 2025	CRMD CorMedix	$0.20	$0.28	+$0.08	$0.28	$29.88 million	$39.74 million
8/6/2025	Q2 2025	LNTH Lantheus	$1.65	$1.57	-$0.08	$1.12	$389.69 million	$378.05 million
8/6/2025	Q2 2025	PTGX Protagonist Therapeutics	-$0.53	-$0.55	-$0.02	-$0.55	$8.32 million	$5.55 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	N/A
CRMD CorMedix	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKRO Akero Therapeutics	0.02	12.66	12.66
CRMD CorMedix	N/A	7.82	7.52
LNTH Lantheus	0.49	4.29	4.07
PTGX Protagonist Therapeutics	N/A	16.97	16.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKRO Akero Therapeutics	N/A
CRMD CorMedix	34.18%
LNTH Lantheus	99.06%
PTGX Protagonist Therapeutics	98.63%

Insider Ownership

Company	Insider Ownership
AKRO Akero Therapeutics	7.07%
CRMD CorMedix	5.30%
LNTH Lantheus	1.50%
PTGX Protagonist Therapeutics	4.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKRO Akero Therapeutics	30	79.99 million	74.33 million	Optionable
CRMD CorMedix	30	74.65 million	70.69 million	Optionable
LNTH Lantheus	700	67.99 million	66.97 million	Optionable
PTGX Protagonist Therapeutics	120	62.21 million	59.16 million	Optionable

CRMD, AKRO, LNTH, and PTGX Headlines

Recent News About These Companies

Invesco Ltd. Has $41.57 Million Position in Protagonist Therapeutics, Inc. $PTGX

August 20 at 3:42 AM | marketbeat.com

Deutsche Bank AG Has $3.18 Million Holdings in Protagonist Therapeutics, Inc. $PTGX

August 20 at 3:24 AM | marketbeat.com

E Fund Management Co. Ltd. Sells 71,950 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

August 18 at 5:10 AM | marketbeat.com

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Bought by Public Sector Pension Investment Board

August 15, 2025 | marketbeat.com

Informed Momentum Co LLC Takes Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

August 13, 2025 | marketbeat.com

Knott David M Jr Purchases 23,632 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

August 12, 2025 | marketbeat.com

Does Protagonist Therapeutics’ (PTGX) Widening Loss and Shelf Registration Signal a Strategic Pivot?

August 12, 2025 | finance.yahoo.com

Wedbush Issues Optimistic Estimate for PTGX Earnings

August 12, 2025 | americanbankingnews.com

Wedbush Has Positive Estimate for PTGX Q3 Earnings

August 11, 2025 | marketbeat.com

Wedbush Expects Higher Earnings for Protagonist Therapeutics

August 9, 2025 | marketbeat.com

7PTGX : What 4 Analyst Ratings Have To Say About Protagonist...

August 8, 2025 | benzinga.com

JMP Securities Forecasts Strong Price Appreciation for Protagonist Therapeutics (NASDAQ:PTGX) Stock

August 8, 2025 | marketbeat.com

Protagonist Therapeutics files automatic mixed securities shelf

August 7, 2025 | msn.com

Protagonist (PTGX) Q2 Revenue Falls 26%

August 7, 2025 | fool.com

Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates

August 6, 2025 | zacks.com

Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 6, 2025 | accessnewswire.comA

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Holdings Raised by XTX Topco Ltd

August 5, 2025 | marketbeat.com

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Rating of "Buy" by Analysts

August 4, 2025 | marketbeat.com

Jupiter Asset Management Ltd. Makes New $8.13 Million Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

August 4, 2025 | marketbeat.com

GSA Capital Partners LLP Acquires New Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

August 4, 2025 | marketbeat.com

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Holdings Raised by Envestnet Asset Management Inc.

August 4, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRMD, AKRO, LNTH, and PTGX Company Descriptions

Akero Therapeutics NASDAQ:AKRO

$48.29 +0.34 (+0.71%)

Closing price 04:00 PM Eastern

Extended Trading

$49.00 +0.70 (+1.46%)

As of 04:52 PM Eastern

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

CorMedix NASDAQ:CRMD

$13.56 +0.04 (+0.30%)

Closing price 04:00 PM Eastern

Extended Trading

$13.54 -0.02 (-0.15%)

As of 04:52 PM Eastern

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Lantheus NASDAQ:LNTH

$59.16 +3.02 (+5.38%)

Closing price 04:00 PM Eastern

Extended Trading

$59.08 -0.08 (-0.13%)

As of 05:12 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Protagonist Therapeutics NASDAQ:PTGX

$56.04 -0.19 (-0.34%)

Closing price 04:00 PM Eastern

Extended Trading

$56.00 -0.04 (-0.07%)

As of 04:10 PM Eastern

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time